Literature DB >> 11315462

Transmission of wild poliovirus type 2--apparent global interruption.

.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11315462

Source DB:  PubMed          Journal:  Wkly Epidemiol Rec        ISSN： 0049-8114


× No keyword cloud information.
  20 in total

1.  Circulation of endemic type 2 vaccine-derived poliovirus in Egypt from 1983 to 1993.

Authors:  Chen-Fu Yang; Tary Naguib; Su-Ju Yang; Eman Nasr; Jaume Jorba; Nahed Ahmed; Ray Campagnoli; Harrie van der Avoort; Hiroyuki Shimizu; Tetsuo Yoneyama; Tatsuo Miyamura; Mark Pallansch; Olen Kew
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

2.  The risks, costs, and benefits of possible future global policies for managing polioviruses.

Authors:  Kimberly M Thompson; Radboud J Duintjer Tebbens; Mark A Pallansch; Olen M Kew; Roland W Sutter; R Bruce Aylward; Margaret Watkins; Howard E Gary; James Alexander; Hamid Jafari; Stephen L Cochi
Journal:  Am J Public Health       Date:  2008-05-29       Impact factor: 9.308

3.  Sabin and wild type polioviruses from children who presented with acute flaccid paralysis in Nigeria.

Authors:  A O Adedeji; I O Okonko; F D Adu
Journal:  Afr Health Sci       Date:  2012-09       Impact factor: 0.927

4.  Preeradication vaccine policy options for poliovirus infection and disease control.

Authors:  Kimberly M Thompson; Mark A Pallansch; Radboud J Duintjer Tebbens; Steve G Wassilak; Jong-Hoon Kim; Stephen L Cochi
Journal:  Risk Anal       Date:  2013-03-05       Impact factor: 4.000

5.  Oral poliovirus vaccine evolution and insights relevant to modeling the risks of circulating vaccine-derived polioviruses (cVDPVs).

Authors:  Radboud J Duintjer Tebbens; Mark A Pallansch; Jong-Hoon Kim; Cara C Burns; Olen M Kew; M Steven Oberste; Ousmane M Diop; Steven G F Wassilak; Stephen L Cochi; Kimberly M Thompson
Journal:  Risk Anal       Date:  2013-03-07       Impact factor: 4.000

6.  Modeling poliovirus risks and the legacy of polio eradication.

Authors:  Kimberly M Thompson
Journal:  Risk Anal       Date:  2013-03-28       Impact factor: 4.000

7.  The polio eradication endgame: Why immunization and continued surveillance is critical.

Authors:  T F Booth; E Grudeski; A McDermid; J Rotondo
Journal:  Can Commun Dis Rep       Date:  2015-10-01

8.  Maintenance and Intensification of Bivalent Oral Poliovirus Vaccine Use Prior to its Coordinated Global Cessation.

Authors:  Radboud J Duintjer Tebbens; Lee M Hampton; Steven G F Wassilak; Mark A Pallansch; Stephen L Cochi; Kimberly M Thompson
Journal:  J Vaccines Vaccin       Date:  2016-10-03

9.  Immunogenicity and Safety of Inactivated Sabin-Strain Polio Vaccine "PoliovacSin": Clinical Trials Phase I and II.

Authors:  Anastasia Piniaeva; Georgy Ignatyev; Liubov Kozlovskaya; Yury Ivin; Anastasia Kovpak; Alexander Ivanov; Anna Shishova; Liliia Antonova; Yusuf Khapchaev; Irina Feldblium; Olga Ivanova; Aleksandra Siniugina; Aydar Ishmukhametov
Journal:  Vaccines (Basel)       Date:  2021-05-29

10.  Co-circulation and evolution of polioviruses and species C enteroviruses in a district of Madagascar.

Authors:  Mala Rakoto-Andrianarivelo; Sophie Guillot; Jane Iber; Jean Balanant; Bruno Blondel; Franck Riquet; Javier Martin; Olen Kew; Bakolalao Randriamanalina; Lalatiana Razafinimpiasa; Dominique Rousset; Francis Delpeyroux
Journal:  PLoS Pathog       Date:  2007-12       Impact factor: 6.823
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.